ESPharma
ActiveSummary
The computed 12-month bankruptcy probability of ESPharma is 1.8% (moderate). The 2025 annual accounts show equity of €56k and a net result of €40k. Its solvency ranks better than 83% of 18400 sector peers (fiscal year 2025). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
Axes · tick = 2024
Profitability100=
Solvency99▲+15
Growth78
Track record82
Bankruptcy probability, 12 months
1.8%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €4.5k at 30 days acceptable
Liquidity ample (current ratio 3.88 against 2.45 in 2024; short-term debt: 25.8% and cash: 35.4% of total assets), and 25.8% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
74.2%
Return on assets
53.7%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 2 filingsDeviation from the deadline
2025
2 d early
2024
3 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Accepting this client? The AML file with identity, beneficial owners and sanctions lists.AML client file How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed Roughly what is this company worth?Value indication
Financials · fiscal year 2025, micro schema
Equity
€56k▲ 244%
2024 · €16k
Total assets
€75k▲ 174%
2024 · €27k
Net result
€40k▲ 160%
2024 · €15k
Working capital
€56k▲ 244%
2024 · €16k
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20242025
Operating result€20k-€51k▲ 160%
Net result€15k-€40k▲ 160%
Equity€16k-€56k▲ 244%
Total assets€27k-€75k▲ 174%
Debt€11k-€19k▲ 73.0%
Working capital€16k-€56k▲ 244%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result rises in 2025; 2025 is 160% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €75k
Equity
€56k ▲ 244%
Debt
€19k ▲ 73.0%
Debt's share of the balance-sheet total falls from 40.8% to 25.8%. Equity and debt are higher.
Key figures and ratios
Current ratio
3.88▲
2024 · 2.45
Debt to equity
0.35▼
2024 · 0.69
ROE
72.4%▼
2024 · 95.9%
ROA
53.7%▼
2024 · 56.7%
Debt ≤ 1 year
€19k▲
2024 · €11k
Income taxes
€11k▲
2024 · €4k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1k | - | - |
| Other operating charges640/8 | - | €441 | - |
| Gross operating margin9900 | €21k | €51k | ▲ 149% |
| Operating profit (loss)9901 | €20k | €51k | ▲ 160% |
| Financial income75/76B | - | €700 | - |
| Recurring financial income75 | - | €700 | - |
| Financial charges65/66B | €8 | €45 | ▲ 500% |
| Recurring financial charges65 | €8 | €45 | ▲ 500% |
| Profit (loss) for the period before taxes9903 | €20k | €51k | ▲ 163% |
| Income taxes67/77 | €4k | €11k | ▲ 178% |
| Profit (loss) for the period9904 | €15k | €40k | ▲ 160% |
| Profit (loss) for the period to be appropriated9905 | €15k | €40k | ▲ 160% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €27k | €75k | ▲ 174% |
| Current assets29/58 | €27k | €75k | ▲ 174% |
| Amounts receivable after more than one year29 | - | €40k | - |
| Other amounts receivable291 | - | €40k | - |
| Amounts receivable within one year40/41 | €2k | €8k | ▲ 258% |
| Trade receivables40 | €2k | €8k | ▲ 258% |
| Cash at bank and in hand54/58 | €25k | €27k | ▲ 5.9% |
| Deferred charges and accrued income490/1 | - | €189 | - |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €27k | €75k | ▲ 174% |
| Equity10/15 | €16k | €56k | ▲ 244% |
| Contributions10/11 | €2k | €2k | = |
| Profit (loss) carried forward14 | €15k | €54k | ▲ 269% |
| Amounts payable17/49 | €11k | €19k | ▲ 73.0% |
| Amounts payable within one year42/48 | €11k | €19k | ▲ 73.0% |
| Trade debts44 | €160 | €1k | ▲ 601% |
| Suppliers440/4 | €160 | €1k | ▲ 601% |
| Taxes, remuneration and social security45 | €9k | €17k | ▲ 85.8% |
| Taxes450/3 | €9k | €17k | ▲ 85.8% |
| Other amounts payable47/48 | €2k | €841 | ▼ 49.6% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | €15k | €40k | ▲ 160% |
| + Depreciation and write-downs630 | €1k | - | - |
| Operating cash flow (approximation) | €17k | €40k | ▲ 143% |
| Change in cash | - | €1k | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
29-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
28-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
NBB filing
0 of 1 act read
About the unread acts
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Anderlecht · 1 establishment unit since 2024
Ground area
235 m²
Building footprint
87 m²
Volume, LiDAR
904 m³
Parcel 21302A0117/00S003, Brussels · tallest building 17.5 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
ESPharma
since 20242.365.313.524
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21302A0117/00S003 | Brussels | 235 m² | 1 · 87 m² | 17.5 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMA JACK
BE 0875.221.694
Charleroi · Eq €55,519
PIRET-LESSIRE PHARMA
BE 0783.835.026
Charleroi · Eq €55,539
BEUKELEIRS HOLDING
BE 0651.678.068
Vielsalm · Eq €55,503
PHARMACIE LERUTH
BE 0423.593.555
Liège · Eq €55,494
Pharmacie Théodore
BE 1024.584.274
Jette · Eq €55,480
Of 5,221 companies in sector 47730 we hold annual accounts for 3,860. 2,884 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded03-10-2024
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Contact
E-mail
emilie.spilborghs@hotmail.com
Scores and ratios are computed by Checked and are not a credit decision.